Neumora Therapeutics (NMRA) Receivables - Other (2022 - 2024)

Neumora Therapeutics' Receivables - Other history runs 3 years deep, the most recent figure standing at $1.6 million for Q2 2024.

• In Q2 2024, Receivables - Other changed N/A year-over-year to $1.6 million; the TTM figure through Jun 2024 stood at $1.6 million (changed N/A YoY), while the FY2023 annual figure was $939000.0, up 2.18% from the prior year.
• Receivables - Other for Q2 2024 stood at $1.6 million, up from $906000.0 in the prior quarter.
• The five-year high for Receivables - Other was $1.6 million in Q2 2024, with the low at $668000.0 in Q3 2023.
• The 3-year median for Receivables - Other is $919000.0 (2022), against an average of $1.0 million.
• Peak annual rise in Receivables - Other reached 2.18% in 2023, while the deepest fall reached 2.18% in 2023.
• Neumora Therapeutics' Receivables - Other stood at $919000.0 in 2022, then advanced by 2.18% to $939000.0 in 2023, then surged by 73.7% to $1.6 million in 2024.
• Business Quant data shows NMRA's Receivables - Other at $1.6 million in Q2 2024, $906000.0 in Q1 2024, and $939000.0 in Q4 2023.